Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial ...
MedPage Today on MSN
Add-On Multicancer Early Detection Test Promising Across Various Cancer Types
BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...
Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...
A clinical trial demonstrated that adding the Galleri multi-cancer early detection blood test to standard screening methods ...
QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including ...
Well, Grail makes a multicancer early-detection test called Galleri that screens for a signal in the blood shared by more ...
More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings ...
A new Galleri blood test detected 75% of cancers without current screening options, with over half found in early stage I or ...
The blood test, which can be given annually, was correctly identified that trial participants had cancer in two-thirds of ...
Grail is on a mission to have its cancer blood test become a core part of U.S. screening for a range of tumors. Now, it’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback